Apogee Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 135.07 USD (Sep 3, 2026, 4:00 PM EDT) · Market cap 10.19B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Rα for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Details
| Name | Apogee Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 261 |
| Founded | 2022 |
| Ipo Date | 2023-07-14 |
| Ceo | Michael Henderson |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US03770N1019 |
| Cusip | 03770N101 |
| Cik | 1974640 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Michael Thomas Henderson M.D. | Chief Executive Officer and Director |
| Jane Pritchett V. Henderson | Chief Financial Officer |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Noel Kurdi | Vice President of Investor Relations |
| Matthew Batters J.D. | Chief Legal Officer and Corporate Secretary |
| Emily Cox | Senior Vice President and Head of People |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs and Toxicology |
| Monica Forbes | Senior Vice President of Finance |
Contact
| Address | Building 17, Suite 102b, Waltham, Massachusetts 02453, United States |
| Phone | 650 394 5230 |
| Website | https://www.apogeetherapeutics.com |